
Opinion|Videos|October 14, 2024
Unmet Needs and Clinical Considerations for HER2+ NSCLC
Key Takeaways
- Effective therapies that penetrate the blood-brain barrier and target resistant tumor cells are needed in lung cancer brain metastases management.
- Current treatments often provide limited survival benefits and significant side effects, highlighting the need for improved therapeutic options.
Panelists discuss how persistent unmet needs in HER2-directed therapy for NSCLC present opportunities for future research and pipeline therapies, potentially addressing challenges such as treatment resistance, improved efficacy, or reduced toxicity profiles.
Advertisement
Video content above is prompted by the following:
- What unmet needs persist in this space and what opportunities exist for future research or pipeline therapies?
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
2025 Nobel Prize in Medicine Honors Discoveries Behind Regulatory T Cells
2
FDA Expands Roflumilast Use for Atopic Dermatitis to Children Aged 2 to 5 Years
3
Aggressive Therapy Recommendations Following the STRONG-HF Trials: Stephen J. Green, MD
4
Pricing and Insurance Networks in Outpatient Surgery Markets
5